Nephraxis

Sepsis-associated acute kidney injury (SA-AKI) represents a major unmet medical need, each year affecting an estimated 3–5 million individuals in Europe and the U.S. The global acute kidney injury treatment market is valued at approximately USD 2.5 billion and growing. SA-AKI is associated with substantial morbidity and mortality. Currently, patients only receive supportive care. Consequently, many patients need to undergo dialysis with associated risks of permanent kidney damage, large physical and psychological burden for the patient and family as well as a financial impact on the health care system. With no pharmacological therapies currently available, a medicinal product treating SA-AKI will serve a high unmet medical need.

Nephraxis aims to develop a first-in-class, mechanism-based, pharmacological treatment for SA-AKI improving kidney function, preventing chronic kidney disease and the need for and the time on dialysis effectively resulting in reduced days in hospital and intensive care unit (ICU). Our offer concerns a non-disclosed drug candidate of established safety, with data and strategy to support IP protection, and covered by a development plan to acquire preclinical and clinical proof-of-concept. As such, it will be positioned for accelerated development and potential expedited market entry with protection, meeting a high unmet need. In addition, our plan includes opportunities for lifecycle management and for ensuring sustained impact.